Home

BioNOOX intends to become the LEADING PROVIDER of THERAPEUTICS addressing HIGH UNMET MEDICAL NEEDS in SEVERE SKIN INFLAMMATION DISORDERSimpacting patients’ lives and treatment outcomes

BioNOOX develops innovative therapeutics to address HIGH UNMET MEDICAL NEEDS in SEVERE SKIN INFLAMMATION DISORDERSimpacting patients’ lives and treatment outcomes

INNOVATION

THERAPEUTICS

HIGH

UNMET

NEEDS

SKIN INFLAMMATION

THE CHALLENGE OF TREATING RADIATION DERMATITIS, A SIGNIFICANT UNMET NEED…

“The last few decades have seen a dramatic improvement in the survival of breast cancer patients, due largely to treatment escalation, especially with the addition of new drugs such as targeted agents. Whilst a greater number of patients now survive breast cancer, attention must switch to improving patients quality of life (QoL), limiting morbidity without compromising patient survival, and avoiding unnecessary overtreatment. Trials focusing on treatment de-escalation are therefore of growing importance.” ESMO (European Society for Medical Oncology) 2018 Congress Daily Reporter, 21.10.2018

Breast cancer : effective treatments but severe side effects

1 Porock D & Kristjanson L. European Journal of Cancer Care 1999;8:143-153

2 Kedge E. Radiography 2009;15:247-257

3 Wells M et al. Radiation skin reactions. In: Faithfull S et al.Supportive care in radiotherapy. London: Elsevier; 2003. p. 135-159

4 Naylor W & Mallett J. European Journal of Oncology Nursing 2001;5(4):221-233

5 López E, Nuñez MI, Guerrero MR, et al. Breast Cancer Res Treat. 2002;73(2):127

11 Russo G et al. The Oncologist 2008;13:886-898

15 Marta GN et al. Sao Paulo Med J. 2011;129(2):116-117 “In 10% to 30% of [breast cancer patients] cases, radiodermatitis leads to temporary interruption of treatment delivery, which negatively affects our understanding of radiobiology.”

Founded in 2011, BioNOOX Therapeutics is a Swiss biopharmaceutical company led by an experienced team with a proven track record in biotech startup build-up with strong growth and value creation. BioNOOX Therapeutics have developed an innovative and proprietary approach to prevent and treat skin inflammation disorders which affect hundreds of millions of people in the world. The clinical development program focuses on supportive care in inflammatory skin disorders, induced e.g. by anticancer therapies, autoimmune diseases or infectious diseases. Those skin inflammations are not properly addressed with the current management options, leaving affected patients with high unmet needs. One of the strengths of BioNOOX is the development of partnerships with several research institutions, to fasten the R&D activities and BioNOOX clinical development program.

TEAM TEAM

BioNOOX Therapeutics’ approach is to develop and maintain a close partnership with various research institutions (academic research laboratories, clinics, pharmaceutical industry), to support efficiently R&D activities and quickly advance our clinical development program.

Leading center for the fight against cancer in Europe, Gustave Roussy Institute brings together on the same site 2,600 professionals whose mission is to treat people with cancer, develop new therapies and spread knowledge in the medical and scientific communities, French and International.

Hospital of proximity and specialty, teaching and research, it is recognized for its reference activities such as the management of cardiovascular and metabolic pathologies, complex infectious and immune pathologies, diseases of the nervous system and mental pathologies , organ and bone marrow transplantation, emergencies, surgery, oncology, and perinatality.

The University of Lausanne is a higher teaching and research institution composed of seven faculties where approximately 14,300 students and 3,000 researchers work and study. UNIL is focused on several academic disciplines, especially Medicine, Life Sciences, Geosciences, Environment, Business, Humanities and Social Sciences.

AP-HP research to continually improve care and develop new treatments. At AP-HP, you get advanced search and you make progress, participating for example, if you wish and under the control of an ethics committee, "clinical trials" or "tests therapeutic ". We have a research foundation whose mission is to fund research projects in our hospitals, in addition to existing resources.

With 200 sites in 38 countries, Eurofins’ mission is to contribute to global Health & Safety. With over 25 years of experience, Eurofins Optimed is a worldwide leader in early clinical trials. Their own ClinPharm Unit and a strong international network enable them to, they provide efficient recruitment of healthy volunteers and patients within Europe.

NOOXYL

NOOXYL® as preventive treatment of radiation dermatitis NOOXYL® preserves skin integrity by avoiding the pro-inflammatory effects of ionizing radiation • NOOXYL® creates a protective layer that maintains skin integrity and reduces trauma and irritation to the irradiated site. • NOOXYL® inhibits the release of pro-inflammatory cytokines and thus avoids the development of an acute inflammatory response. • NOOXYL® limits the global oxidizing stress leading to inflammation. • NOOXYL® prevent the compromised skin from infections thanks to its antibacterial and antiviral properties.

NOOXYL® as curative treatment of radiation dermatitis NOOXYL® regenerates skin integrity by stopping the inflammatory process induced by radiotherapy. • NOOXYL® limits the inflammatory response and cell migration to the site of inflammation by regulating ROS and cytokines release • NOOXYL® creates a protective layer that promotes a moist wound healing environment, leading to a faster re-epithelialization of the skin post therapy. • NOOXYL® reduces pain, redness and swelling to avoid inflammatory worsening in the exposed skin areas.

NOOXYL®, our initial formulation, besides providing a mechanical protection for the damaged skin (like current therapies), will also exert a polypharmacology action, particularly relevant to the pathophysiological processes described in radiation dermatitis and other cancer treatment side effects : - Reactive oxygen species (ROS) scavenging - Targeting of cytokine-mediated inflammation through inhibition of the STAT3 signaling pathway NOOXYL® targets cytokine-mediated inflammation through inhibition of the STAT3 signaling pathway. Cytokines are released when the skin is exposed to aggressions through radiotherapy, targeted cancer therapy, or infection. By inhibiting the release of those cytokines, NOOXYL® reduces the process of skin inflammation and its related toxicities.

c/o LaCité Business Nucleus Avenue de l’Université 24 CH-1005 Lausanne - Switzerland

Copyright © 2020 BioNOOX SA. All Rights Reserved.